Cyprotex reports ‘steady’ progress

MACCLESFIELD-based drug testing firm Cyprotex said that it had made “solid” progress integrating Apredica and Cellumen – the two US-based businesses specialising in in-vitro toxicology bought by the firm in August for approximately £2.68m

In a trading update this morning, the company said that it expected full-year
results to be in line with analysts’ expectations.

Chief executive Dr Anthony Baxter said: ““Following our acquisition of Apredica in August and the introduction of our new CellCiphr(TM) toxicology suite, we are pleased to report good, steady progress in trading.

“We expect our numbers to be in line with market expectations and our ongoing investment programme reflects our continued confidence in the future prospects for Cyprotex.”